TP53 and B-cell chronic lymphocytic leukemia: To evaluate the ability of the CXCR4 antibody to induce cell death in leukemia cells from CLL patients with high risk (CLL-HR), low risk (CLL-LR), as well as with TP53 17pDel status, we treated samples from patients with these various genetic backgrounds with m15-IgG1 and evaluated cell death after 48 h of culture.